

# Surgical Gut

absorbable by nature  
dependable by Ethicon\*

When the need is for an absorbable suture ETHICON surgical gut is the natural choice.

The natural advantages of surgical gut are enhanced at Ethicon by the use of the most modern technology available.


The result is a suture of unsurpassed purity and uniformity upon which the surgeon can rely.



**ETHICON\***

... leadership in wound repair

inside  
every Baritop can  
are fine radiographs  
waiting  
to get out



The excellent fluidity and optimum concentration of Baritop 100 form a unique combination of properties which results in superior visualisation of mucosal detail. Carbon dioxide is incorporated as an effervescent agent to aid double-contrast procedures and enhance the exceptional palatability of the suspension.

Baritop 100 is the modern liquid barium specifically formulated to match the sophistication of present day equipment and techniques.

The elegant barium suspension at 100% w/v in convenient 300ml. cans.

## **Baritop 100**

**world's finest micronised  
barium suspension**

Further information available  
on request from

**C** Concept Pharmaceuticals Limited  
Russell House  
59/61 High Street  
Rickmansworth WD3 1EZ

Baritop is a registered trade mark

# **colofac<sup>®</sup>** **is an antispasmodic** **that is not related** **to atropine** **Name another!**

In the treatment of *the irritable colon syndrome* Colofac acts directly and selectively on colonic smooth muscle in spasm. Unlike the anticholinergic antispasmodics the action of Colofac is independent of the autonomic nervous system. Consequently Colofac relieves abdominal pain, discomfort after meals and disordered bowel function without causing the typical atropine-like side-effects of dry mouth, blurred vision and drowsiness. Each tablet of Colofac contains 100 mg. Mebeverine. Further information is available on request.

**colofac—the direct-acting antispasmodic**  
mebeverine

# ONLY COTAZYM

## has accurately assayed lipase activity

Pancreatic replacement therapy  
can be adjusted to cover the exact amount  
of fat in the patient's diet

**Cotazym** is the only pancreatic extract with known, measurable and constant lipase activity, in addition to adequate measured amounts of trypsin and amylase. It allows simple but accurate estimation of dosage ensuring greater control over dietary intake.

**Each capsule contains:**

lipase sufficient to digest 17g dietary fat  
trypsin sufficient to digest 34g dietary protein  
amylase sufficient to digest 40g dietary starch.

**Indications:**

pancreatic deficiency states including post-gastrectomy malabsorption, fibrocystic disease and gastro-intestinal disorders resulting in steatorrhoea.

**Dosage:**

dosage is calculated on the fat digesting power of the lipase. 2 to 3 capsules taken with each main meal and one capsule with a snack is sufficient to cover normal daily fat intake. The contents of the capsule should be sprinkled over the food.



Organon Laboratories Ltd · Crown House · Morden · Surrey

# CAVED-S TABLETS

## SOME TRIAL SUMMARIES

### GUT 1968-9 48-51

#### SUMMARY

In a double blind clinical trial in which 54 patients\* were included, the effect of deglycyrrhizinized liquorice was investigated. Duodenal ulcer cases showed marked symptomatic improvement, with radiological healing demonstrable in a few cases.

\*48 Duodenal ulcer patients: 6 gastric ulcer patients.

Further confirmation of the activity of the drug was obtained from the treatment of six cases of gastric ulcer all of which showed extensive healing. Radiology demonstrated that the effect of the drug was spasmolytic in all duodenal ulcer patients, and that the side-effects were minimal. The great advantage of the treatment is that patients can be treated as ambulant and with a minimum loss of work.

### GUT 1971-72 449-451

#### SUMMARY

In our study no significant differences were found between the placebo and the treated groups.

The differences between the reported results are not easy to explain. Crossover trials in patients with duodenal ulcer are not easy to evaluate. In particular, it is not clear how after one month of reportedly successful therapy with complete relief of symptoms another drug (placebo) can be evaluated using clinical criteria. Even if the placebo is used first, the attack may be expected to subside within a month in part of the group.

In view of the conflicting reports more studies will have to be performed before a therapeutic effect can be attributed to deglycyrrhizinized liquorice in patients with duodenal ulcer.

It is not clear whether our results reflect on the efficacy of liquorice extract after the removal of carbenoxolone or merely on its efficacy in duodenal as contrasted to gastric ulcer. In common with others we found no side effects attributable to treatment with deglycyrrhizinized liquorice.

### GUT 10 299-302 1969

#### SUMMARY

In a double-blind clinical trial of deglycyrrhizinized liquorice 16 patients with gastric ulcer received the active drug for four weeks in a dose of 760 mg thrice daily and 17 the placebo. All patients, except four from each group who remained ambulant, were treated as outpatients. The results of the trial were assessed by the change in the size of the ulcer crater on barium meal before and after treatment.

Of the patients given the active drug, on average the size of the ulcer niche was reduced by 78%; in six patients (44%) the crater disappeared radiologically. In contrast the average reduction in size of the ulcer niche of the placebo group was 34% and in only one (6%) did the ulcer disappear. The difference in the reduction in ulcer size in favour of the treated group compared with the control group is statistically significant ( $P < 0.001$ ). None of the patients developed oedema and there was no excessive weight gain.

A pilot trial using Caved-(S) in a dose containing 760 mg of deglycyrrhizinized liquorice thrice daily for one month showed no toxic effects on fluid and electrolyte balance in 10 patients.


Protective Action of Deglycyrrhizinized Liquorice on the Occurrence of Stomach Ulcers in Pylorus-Ligated Rats. *Scand. J. Gastroent.*, 6, 683-686.

The effect of graded doses of a deglycyrrhizinized liquorice extract (d.Li.) was studied on the frequency of stomach ulcers and the secretion of gastric juice in pylorus-ligated rats. 25-50 mg of d.Li. given intraperitoneally reduced considerably the number of ulcers in comparison with the control group of rats without any significant changes in gastric secretion. Higher doses—100-200 mg—gave complete protection against the development of gastric ulcers and also reduced the output of gastric juice. The results give strong support for the existence of an ulcer-protecting principle in the d.Li.

*Key-words:* Gastric secretion; gastric ulcers; liquorice; pylorus-ligated rats.

*Dept. of Pharmacology, Karolinska institutet, S-104 01 Stockholm 60, Sweden.*

**TILLOTTS LABORATORIES 44 LUPUS ST LONDON S.W.1**



**actively  
heals  
peptic ulcer**


# **GEFARNIL**

**the systemic treatment  
for peptic ulcers**

Gefarnil is unique. Its action is systemic. Gefarnil treats peptic ulcer by acting on the ulcer via the blood stream. Its action is quite specific. By repairing the tissue damage of gastric and duodenal ulceration, Gefarnil heals the ulcer.



Gefarnil is gefarnate in capsules of 50 mg. Gefarnil is manufactured under licence from Istituto de Angeli SpA, Milan, Italy by The Crookes Laboratories Ltd., Basingstoke, Hants, from whom full information is available.



## Flatulent dyspepsia. And not for the first time.

Or the second, or the third. The patient probably has a history of repeated visits to her general practitioner, and a variety of treatments have failed to resolve the cause of her symptoms.

After investigation, you will wish to establish a treatment that will take account of the underlying problem. In such a patient this is likely to be a disturbance in gastroduodenal motility. Maxolon restores normal gastro-

duodenal motility, and clinical experience confirms that 4 out of 5 patients with dyspeptic symptoms benefit from treatment with Maxolon.

*Full information on the use of Maxolon in hospitals is available on request.*

Maxolon\* (metoclopramide) is a product of



**Beecham Research  
Laboratories**

Brentford, England

\*regd.



## **Maxolon** for flatulent dyspepsia.

---

# Nutrizym<sup>®</sup>

---

**unique two-stage replacement or supplemental therapy  
in pancreatic insufficiency**

*Extensive clinical evidence\* indicates that Nutrizym is significantly more effective than its competitors in improving fat absorption and protein digestion, and in reducing faecal weight.*

Each Nutrizym tablet has an enteric-coated pancreatic core and a shell of bromelains – proteolytic enzymes of the pineapple – which are active within the pH range of pH3 and pH8 (even pH2 for short periods) and therefore act without loss of enzymatic effectiveness at the low pH found in the stomach.

Following ingestion of the tablet, the bromelains are liberated in the stomach, where proteolytic action is required, and pancreatin is released in the duodenum. Additionally, the bromelains aid digestion in the small intestine where they develop their full proteolytic effect.

Nutrizym is indicated in: pancreatic deficiency states including post-gastrectomy malabsorption, fibrocytic and gastro-intestinal disorders resulting in steatorrhoea.

Nutrizym: each tablet contains Bromelains 50mg. Pancreatin \*\* 4 x N.F. 400mg, and Ox bile 30mg.

\*\* activity equivalent to four times pancreatin B.P.

Dosage: 1 tablet to be taken with meals. Further tablets may be taken according to the degree of pancreatic exocrine insufficiency.

*Full information on request*

---

**E. Merck Limited, Wokingham, Berks.**

---

\*Brit.med.J., 1970, 4, 21    Medical Digest, 1972, 17, 54    Gastroenterologie 1969, 7, 314.

---



# duphalac<sup>®</sup> in lactulose liver failure

*Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut\* describes its role in these terms.*

"Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .  
. . . lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required". \*Gut, 1970, 11: 1043-1048

**The following work on Duphalac in portal systemic encephalopathy has been published:**

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1: 890-892

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2: 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2: 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76: 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11: 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281: 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18: 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose  
*Therapeutische Umschau und medizinische Bibliographie*, 1969, 26: 275-277

Lactulose treatment of chronic hepatportal encephalopathy: a clinical and electroencephalographic study  
*Acta medica Scandinavica*, 1970, 187: 337-346

The value of EEG frequency analysis in hepatic encephalopathy  
*J. Ryl. Coll. Surg. Edinb.*, 1970, 15: 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy  
*Quarterly Journal of Medicine*, 1970, 39: 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy  
*Gastroenterology*, 1970, 59: 827-832

**Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.**

Further information available on request.

**duphar** DUPHAR LABORATORIES LIMITED WEST END SOUTHAMPTON TEL 04218 2281  
PHILIPS-DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271



# The single solution

for parenteral nutrition


## Aminoplex 5

1 litre three times per day provides 15g. of utilisable nitrogen and 3000K calories; the nutrient content being derived from synthetic L-Form amino acids, sorbitol and alcohol.

### Geistlich Chester

*In co-operation with Salvia-Werk  
G.m.b.H., Homburg/Saar, W. Germany.*

Medical literature  
available from:  
**Geistlich Sons Ltd.,  
Newton Bank,  
Long Lane,  
Chester CH2 3QZ.  
Telephone  
Chester 47534-7**



# Research results are now universally available within six weeks

**The International Research Communications System is a completely new service for scientists. It provides a simple method for the rapid interchange of research results anywhere in the world and it also provides a central data bank in which the results of all research can be stored. This major new System has been devised with the guidance and support of many leading research workers. In the first instance the System is limited to research in medical science, medical biochemistry and physiology. The System covers work destined for full publication elsewhere together with communications of other valid and potentially useful material—negative results for example—which often go unpublished for lack of space.**

### How the System operates.

On completion of a piece of research work, the research worker prepares a 500 word communication. He submits this and a cheque for £3/£8 (or the equivalent sum in any local convertible currency), which covers the cost of providing 25 reprints to him.

All research which meets basic standards of scientific validity and value will be accepted. If the communication is rejected, it is immediately returned – together with the cheque – to the author. If it is accepted 25 reprints are immediately printed and sent to the author, and the communication is published in the System, within 15–45 days, in the following ways:

- 1 **Classified List.** The descriptive title of the communication and the name of the author is included in the monthly Classified List. With medical science divided into 45 main categories and about 800 sub categories a scientist can quickly find the titles of communications shown in the list that refer to his own subject area.  
This Classified List provides a simple form of immediate access to the whole System.
- 2 **Category Compendium.** Every month all communications received are divided into the 45 main categories of medical science and made available in full, in separate folders for each category. A subscriber can receive the monthly Category Compendium for any one or more of the 45 categories he may wish to specify.
- 3 **Journal.** The 100 or so most widely topical and significant communications received each month from across the whole field of medical science are selected for special publication in full in

The Journal of International Research Communications. As the Journal also contains the complete monthly Classified List it not only provides a review of major developments in medicine but also provides access to all communications in the System.

- 4 **Library Compendium.** Libraries and certain other subscribers will want access in full to all communications in the System without having to request reprints from the publishers. This is available for subscribers to the monthly Library Compendium which includes every communication in full. The Library Compendium comes in micro film form and is available in any kind of cassette the subscriber may wish to specify.
- 5 **Reprints.** All communications included in the System are at all times immediately available from the publishers. (Alternatively a research worker can merely refer to a copy of the Library Compendium). The reprint service is equally available for past communications as for current ones. At the end of each year the monthly Classified Lists are re-issued in a single Annual Cumulative List to make reference to past work particularly easy.

Communications to the System may be submitted as from December 1st 1972. The System will be published monthly commencing on 1st March 1973.

If you would like more information about this new System – or if you would like to submit a communication for incorporation in the System, please complete the form shown below.

*IRCS*

International Research Communications System  
P.O. Box 500, St Leonard's House, Lancaster, England  
(other IRCS offices are located in U.S.A. and Japan)

I have read your advertisement.  
Please send me full details.

I enclose a communication I would like to  
submit for publication by the System.

Name .....

Address .....

(please print) .....

.....

**The Board of Editorial Consultants for the International Research Communications System are:**  
Professor L. Pauling, *Stanford University*; Professor U. S. von Euler, *University of Stockholm*; Professor P. Beeson, *University of Oxford*; Professor R. Calne, *University of Cambridge*; Professor J. Adams, *George Washington University*; Professor J. C. Beck, *McGill University*; Professor E. Stead, *Duke University*; Professor B. K. Anand, *All India Institute of Medical Research*; Professor F. Gross, *Heidelberg University*; Professor W. I. Cranston, *St. Thomas's Hospital*; Professor E. M. Campbell, *McMaster University*; Professor W. J. Oliver, *University of Michigan*; Professor Sir Charles Dodds, *University of London*; Professor S. Karim, *Makrers University*; Professor P. Dejours, *National Centre of Scientific Research, Strasbourg*